Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA" (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is… Read more
Tonix Pharmaceuticals Holding Corp (TNXP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.125x
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has a cash flow conversion efficiency ratio of -0.125x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.78 Million) by net assets ($231.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tonix Pharmaceuticals Holding Corp - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tonix Pharmaceuticals Holding Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MedinCell S.A
PINK:MDCLF
|
0.465x |
|
Lagardere SCA
PA:MMB
|
0.943x |
|
Kingstone Companies Inc
NASDAQ:KINS
|
0.241x |
|
Bookook Sec
KO:001270
|
-0.102x |
|
Bioneer Corporation
KQ:064550
|
0.004x |
|
Ningbo Joy Intelligent Logistics Technology Co.Ltd.
SHE:301198
|
0.017x |
|
CIVEO CORP. DL -01
F:44C1
|
N/A |
|
Minera Valparaiso S.A.
SN:MINERA
|
0.027x |
Annual Cash Flow Conversion Efficiency for Tonix Pharmaceuticals Holding Corp (2008–2024)
The table below shows the annual cash flow conversion efficiency of Tonix Pharmaceuticals Holding Corp from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $139.56 Million | $-60.92 Million | -0.437x | +54.84% |
| 2023-12-31 | $105.53 Million | $-102.00 Million | -0.967x | -104.24% |
| 2022-12-31 | $207.18 Million | $-98.05 Million | -0.473x | -37.00% |
| 2021-12-31 | $218.72 Million | $-75.56 Million | -0.345x | +37.65% |
| 2020-12-31 | $87.65 Million | $-48.57 Million | -0.554x | +80.44% |
| 2019-12-31 | $9.42 Million | $-26.68 Million | -2.833x | -179.72% |
| 2018-12-31 | $23.66 Million | $-23.97 Million | -1.013x | -30.36% |
| 2017-12-31 | $24.62 Million | $-19.13 Million | -0.777x | +47.19% |
| 2016-12-31 | $25.36 Million | $-37.31 Million | -1.471x | -39.30% |
| 2015-12-31 | $40.26 Million | $-42.53 Million | -1.056x | -66.91% |
| 2014-12-31 | $36.09 Million | $-22.84 Million | -0.633x | +51.61% |
| 2013-12-31 | $6.51 Million | $-8.52 Million | -1.308x | +78.05% |
| 2012-12-31 | $958.71K | $-5.71 Million | -5.959x | -654.41% |
| 2011-12-31 | $-2.45 Million | $-2.64 Million | 1.075x | -66.04% |
| 2010-12-31 | $-5.68K | $-17.98K | 3.165x | +236.78% |
| 2009-12-31 | $12.04K | $-27.87K | -2.314x | -321.32% |
| 2008-12-31 | $42.91K | $-23.57K | -0.549x | -- |